Hemanext Continues European Rollout of Hemanext ONE® RBC Processing and Storage System
Summary
Additional endpoints such as mean change in hemoglobin and hematocrit, quality of life (QoL), serum ferritin (during first 12 months), and the impact of hypoxic RBCs on iron overload will all be evaluated and compared to this cohort’s results for the same parameters with conventionally stored RBCs.Dr. As part of its commercialization and sales ramp up program, Hemanext recently signed agreements with leading healthcare distributors in Italy and the Nordics.About HemanextHemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. In its early years, multiple grants from the U.S. National Institutes of Health (NIH) enabled the company to demonstrate the feasibility of hypoxic RBC storage, develop its first prototype system, and conduct in vivo research. [1]In the United States, the product remains available for investigational use only, pending market authorization from the FDA.Preclinical data shows that the HEMANEXT ONE system can reduce oxygen saturation of RBCs to 20% or below and maintain this level throughout storage up to 42 days, demonstrating positive impacts on multiple in vitro metrics of RBC quality. [2] Clinical studies are underway to determine the impact of hypoxic RBCs on patient outcomes and estimate potential cost savings from expected improvements in care and reductions in transfusion volumes.